APA (7th ed.) Citation

Isa, F., Gonzalez Ortiz, A. M., Meyer, J., Hamilton, J. D., Olenchock, B. A., Brackin, T., . . . Dakin, P. (2025). Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: A prospective, open-label, phase 2, randomised controlled trial. The Lancet infectious diseases, 25(1), 52-67. https://doi.org/10.1016/S1473-3099(24)00421-3

Chicago Style (17th ed.) Citation

Isa, Flonza, et al. "Effect of Timing of Casirivimab and Imdevimab Administration Relative to MRNA-1273 COVID-19 Vaccination on Vaccine-induced SARS-CoV-2 Neutralising Antibody Responses: A Prospective, Open-label, Phase 2, Randomised Controlled Trial." The Lancet Infectious Diseases 25, no. 1 (2025): 52-67. https://doi.org/10.1016/S1473-3099(24)00421-3.

MLA (9th ed.) Citation

Isa, Flonza, et al. "Effect of Timing of Casirivimab and Imdevimab Administration Relative to MRNA-1273 COVID-19 Vaccination on Vaccine-induced SARS-CoV-2 Neutralising Antibody Responses: A Prospective, Open-label, Phase 2, Randomised Controlled Trial." The Lancet Infectious Diseases, vol. 25, no. 1, 2025, pp. 52-67, https://doi.org/10.1016/S1473-3099(24)00421-3.